Latest Insider Transactions at Cytosorbents Corp (CTSO)
This section provides a real-time view of insider transactions for Cytosorbents Corp (CTSO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cytosorbents Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cytosorbents Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2024
|
Peter J Mariani Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+4.75%
|
$0
$0.96 P/Share
|
|
Dec 12
2024
|
Peter J Mariani Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+4.98%
|
$0
$0.89 P/Share
|
|
Dec 11
2024
|
Peter J Mariani Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
11,363
+3.05%
|
$0
$0.89 P/Share
|
|
Aug 14
2024
|
Peter J Mariani Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+36.81%
|
-
|
|
Apr 02
2024
|
Phillip P. Chan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
96,000
+7.61%
|
-
|
|
Apr 02
2024
|
Vincent Capponi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
81,000
+10.86%
|
-
|
|
Apr 02
2024
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+10.87%
|
-
|
|
Apr 02
2024
|
Efthymios Deliargyris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,000
+12.97%
|
-
|
|
Dec 13
2023
|
Alan D. Sobel Director |
BUY
Open market or private purchase
|
Direct |
22,557
+18.13%
|
$22,557
$1.33 P/Share
|
|
Dec 13
2023
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
75,188
+6.57%
|
$75,188
$1.33 P/Share
|
|
Dec 13
2023
|
Jiny Kim Director |
BUY
Open market or private purchase
|
Direct |
7,519
+8.81%
|
$7,519
$1.33 P/Share
|
|
Dec 13
2023
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
37,594
+7.44%
|
$37,594
$1.33 P/Share
|
|
Dec 13
2023
|
Edward Raymond Jones Director |
BUY
Open market or private purchase
|
Direct |
7,519
+7.8%
|
$7,519
$1.33 P/Share
|
|
Dec 13
2023
|
Michael G. Bator Director |
BUY
Open market or private purchase
|
Direct |
37,594
+23.07%
|
$37,594
$1.33 P/Share
|
|
Dec 13
2023
|
Vincent Capponi President and COO |
BUY
Open market or private purchase
|
Direct |
18,797
+3.12%
|
$18,797
$1.33 P/Share
|
|
Dec 13
2023
|
Efthymios Deliargyris Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
22,557
+6.08%
|
$22,557
$1.33 P/Share
|
|
Sep 18
2023
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+9.23%
|
-
|
|
Aug 07
2023
|
Michael G. Bator Director |
BUY
Open market or private purchase
|
Direct |
2,000
+1.13%
|
$6,000
$3.18 P/Share
|
|
Aug 04
2023
|
Michael G. Bator Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.15%
|
$3,000
$3.23 P/Share
|
|
Jul 07
2023
|
Efthymios Deliargyris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+14.22%
|
-
|
|
Jul 07
2023
|
Vincent Capponi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
73,000
+11.25%
|
-
|
|
Jul 07
2023
|
Phillip P. Chan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,000
+7.96%
|
-
|
|
May 25
2023
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
3,300
+2.34%
|
$6,600
$2.85 P/Share
|
|
May 10
2023
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+7.52%
|
$30,000
$3.12 P/Share
|
|
Apr 04
2023
|
Vincent Capponi President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+1.92%
|
$20,000
$2.88 P/Share
|
|
Apr 03
2023
|
Phillip P. Chan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,500
+3.18%
|
$61,000
$2.88 P/Share
|
|
Feb 27
2023
|
Alan D. Sobel Director |
SELL
Bona fide gift
|
Indirect |
2,000
-100.0%
|
-
|
|
Feb 27
2023
|
Alan D. Sobel Director |
BUY
Bona fide gift
|
Direct |
2,000
+2.4%
|
-
|
|
Feb 06
2023
|
Al Kraus Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+7.79%
|
$24,000
$2.65 P/Share
|
|
Dec 08
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,859
+0.65%
|
$5,859
$1.26 P/Share
|
|
Dec 07
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,850
+1.09%
|
$9,850
$1.26 P/Share
|
|
Dec 06
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
14,291
+1.6%
|
$14,291
$1.26 P/Share
|
|
Sep 08
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
35,000
+3.88%
|
$35,000
$1.7 P/Share
|
|
Aug 25
2022
|
Jiny Kim Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.4%
|
$1,000
$1.91 P/Share
|
|
Aug 10
2022
|
Efthymios Deliargyris Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
107,000
+17.46%
|
-
|
|
Aug 10
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
79,000
+8.55%
|
-
|
|
Aug 10
2022
|
Vincent Capponi President and COO |
BUY
Grant, award, or other acquisition
|
Direct |
69,000
+11.86%
|
-
|
|
Aug 10
2022
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,500
+12.05%
|
-
|
|
Jun 21
2022
|
Vincent Capponi President and COO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.45%
|
$2,000
$1.8 P/Share
|
|
Jun 16
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,221
+0.29%
|
$2,221
$1.85 P/Share
|
|
Jun 16
2022
|
Vincent Capponi President and COO |
BUY
Open market or private purchase
|
Direct |
3,000
+0.67%
|
$6,000
$2.0 P/Share
|
|
Jun 09
2022
|
Phillip P. Chan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
16,000
+2.05%
|
$32,000
$2.17 P/Share
|
|
Jun 06
2022
|
Kathleen P. Bloch Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
8,700
+20.52%
|
$8,700
$1.9 P/Share
|
|
May 23
2022
|
Vincent Capponi President and COO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.38%
|
$10,000
$2.03 P/Share
|
|
May 18
2022
|
Michael G. Bator Director |
BUY
Open market or private purchase
|
Direct |
11,000
+2.23%
|
$22,000
$2.2 P/Share
|
|
May 16
2022
|
Edward Raymond Jones Director |
BUY
Open market or private purchase
|
Direct |
1,676
+2.02%
|
$3,352
$2.24 P/Share
|
|
May 11
2022
|
Alan D. Sobel Director |
BUY
Open market or private purchase
|
Direct |
10,000
+5.83%
|
$20,000
$2.01 P/Share
|
|
May 06
2022
|
Al Kraus Director |
BUY
Open market or private purchase
|
Direct |
5,000
+3.7%
|
$5,000
$1.96 P/Share
|
|
Apr 05
2022
|
Jiny Kim Director |
BUY
Grant, award, or other acquisition
|
Direct |
69,300
+50.0%
|
-
|
|
Feb 14
2022
|
Alan D. Sobel Director |
BUY
Bona fide gift
|
Indirect |
2,000
+50.0%
|
-
|